AbbVie (ABBV) Stock Forecast & Price Target

AbbVie demonstrated strong commercial performance in its recent quarter, reporting sales of $13.34 billion, which surpassed both internal and consensus expectations, largely driven by robust contributions from its immunology and oncology franchises. The company’s management has increased its fiscal year 2025 earnings per share guidance to a range of $12.09-$12.29, reflecting a solid outlook supported by rising global sales in the neuroscience segment, now projected at approximately $10.7 billion. Additionally, AbbVie's strategic acquisitions and portfolio expansion in neuroscience and oncology are expected to further enhance its growth trajectory, bolstering investor confidence in the company's future financial performance.

AbbVie faces several fundamental challenges that contribute to a negative outlook on its stock, primarily stemming from anticipated commercial execution risks for critical products such as Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. Furthermore, the impending competition from biosimilars for Humira, coupled with limited market penetration of key immunology products and ongoing competitive pressures in the oncology sector, threaten to impact long-term profitability. Additionally, macroeconomic headwinds, particularly in the Aesthetics segment, combined with pipeline delays and potential regulatory setbacks, reinforce concerns over AbbVie's ability to sustain its current growth trajectory.